Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Effects of fibrates in kidney disease: a systematic review and meta-analysis.

Jun M, Zhu B, Tonelli M, Jardine MJ, Patel A, Neal B, Liyanage T, Keech A, Cass A, Perkovic V.

J Am Coll Cardiol. 2012 Nov 13;60(20):2061-71. doi: 10.1016/j.jacc.2012.07.049. Epub 2012 Oct 17. Review.

2.

Antioxidants for chronic kidney disease.

Jun M, Venkataraman V, Razavian M, Cooper B, Zoungas S, Ninomiya T, Webster AC, Perkovic V.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD008176. doi: 10.1002/14651858.CD008176.pub2. Review.

PMID:
23076940
3.

Fibrates for secondary prevention of cardiovascular disease and stroke.

Wang D, Liu B, Tao W, Hao Z, Liu M.

Cochrane Database Syst Rev. 2015 Oct 25;(10):CD009580. doi: 10.1002/14651858.CD009580.pub2. Review.

PMID:
26497361
4.

Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials.

Bonovas S, Nikolopoulos GK, Bagos PG.

PLoS One. 2012;7(9):e45259. doi: 10.1371/journal.pone.0045259. Epub 2012 Sep 19. Review.

5.

Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.

Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, Cass A, Zhang H, Wang H.

Eur Heart J. 2013 Jun;34(24):1807-17. doi: 10.1093/eurheartj/eht065. Epub 2013 Mar 6. Review.

PMID:
23470492
6.

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V.

Lancet. 2010 May 29;375(9729):1875-84. doi: 10.1016/S0140-6736(10)60656-3. Epub 2010 May 10. Review.

PMID:
20462635
7.

Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.

Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B.

Atherosclerosis. 2011 Aug;217(2):492-8. doi: 10.1016/j.atherosclerosis.2011.04.020. Epub 2011 Apr 27. Review.

PMID:
21592479
8.

Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.

Black C, Sharma P, Scotland G, McCullough K, McGurn D, Robertson L, Fluck N, MacLeod A, McNamee P, Prescott G, Smith C.

Health Technol Assess. 2010 Apr;14(21):1-184. doi: 10.3310/hta14210. Review.

9.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

10.

Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials.

Zhang X, Xiang C, Zhou YH, Jiang A, Qin YY, He J.

BMC Cardiovasc Disord. 2014 Feb 17;14:19. doi: 10.1186/1471-2261-14-19. Review.

11.

Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis.

Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P.

J Cardiovasc Pharmacol. 2011 Feb;57(2):267-72. doi: 10.1097/FJC.0b013e318202709f. Review.

PMID:
21052016
12.

Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis.

Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM.

Ann Intern Med. 2012 Aug 21;157(4):251-62. doi: 10.7326/0003-4819-157-4-201208210-00005. Review.

PMID:
22910936
14.

Systematic review on urine albumin testing for early detection of diabetic complications.

Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.

15.

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials.

Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, Craig JC.

BMJ. 2008 Mar 22;336(7645):645-51. doi: 10.1136/bmj.39472.580984.AE. Epub 2008 Feb 25. Review. Erratum in: BMJ. 2009;339:b2951.

16.

Prevention of cardiovascular disease utilizing fibrates--a pooled meta-analysis.

Loomba RS, Arora R.

Am J Ther. 2010 Nov-Dec;17(6):e182-8. doi: 10.1097/MJT.0b013e3181dcf72b.

PMID:
20535009
17.

New fibrate use and acute renal outcomes in elderly adults: a population-based study.

Zhao YY, Weir MA, Manno M, Cordy P, Gomes T, Hackam DG, Juurlink DN, Mamdani M, Moist L, Parikh CR, Paterson JM, Wald R, Yao Z, Garg AX.

Ann Intern Med. 2012 Apr 17;156(8):560-9. doi: 10.7326/0003-4819-156-8-201204170-00003.

PMID:
22508733
18.

Hyperlipidaemia and cardiovascular disease: do fibrates have a role?

Saha SA, Arora RR.

Curr Opin Lipidol. 2011 Aug;22(4):270-6. doi: 10.1097/MOL.0b013e32834701c3. Review.

PMID:
21519250
19.

Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial.

Jardine MJ, Ninomiya T, Perkovic V, Cass A, Turnbull F, Gallagher MP, Zoungas S, Lambers Heerspink HJ, Chalmers J, Zanchetti A.

J Am Coll Cardiol. 2010 Sep 14;56(12):956-65. doi: 10.1016/j.jacc.2010.02.068.

20.

Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline.

Slinin Y, Ishani A, Rector T, Fitzgerald P, MacDonald R, Tacklind J, Rutks I, Wilt TJ.

Am J Kidney Dis. 2012 Nov;60(5):747-69. doi: 10.1053/j.ajkd.2012.07.017. Epub 2012 Sep 19. Review.

PMID:
22999165

Supplemental Content

Support Center